NBL-012

N/A

Report date: 2022/05/07 10:55:29

Base Information

Drug NameNBL-012
Drug Alias NameNBL-012NBL012
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionInterleukin-23 subunit p19 inhibitors
TargetsInterleukin-23 subunit p19
Therapy Area/IndicationsAutoimmune DiseasesPsoriasisHidradenitis Suppurativa
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesCSPC Pharmaceutical Group Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesNovarock Biotherapeutics LtdFlame Biosciences IncShanghai Xinshi Biological Medicine Co Ltd
Inactive CompaniesN/A
Active IndicationsAutoimmune DiseasesPsoriasisHidradenitis Suppurativa
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A